TrialRheumatology (Oxford, England)2021

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.

Josef S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.